Saniona ABCHIX:SANIOS 66 EV-to-FCF is 7.24 as of Jul. 04, 2026. GuruFocus rates CHIX:SANIOS with a GF Score™ of 66/100 and a GF Value™ of kr26.79 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 332 Biotechnology companies, Saniona AB ranks better than 63.25% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Saniona AB's Enterprise Value is kr1,305.2 Mil.
Saniona AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr180.3 Mil. Therefore, Saniona AB's EV-to-FCF for today is 7.24.
The historical rank and industry rank for Saniona AB's EV-to-FCF or its related term are showing as below:
CHIX:SANIOs'
s EV-to-FCF Range Over the Past 10 Years
Min: -236.08 Med: -3.68 Max: 274.92
Current: 7
During the past 13 years, the highest EV-to-FCF of Saniona AB was 274.92. The lowest was -236.08. And the median was -3.68.
CHIX:SANIOs's EV-to-FCF is ranked better than 63.25% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs CHIX:SANIOs: 7.00
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Saniona AB's share price for today is kr12.75.
Saniona AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Saniona AB EV-to-FCF Related Terms
Saniona AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Saniona AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SANIOS vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Saniona AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Saniona AB's EV-to-FCF falls into.
Saniona AB's current Enterprise Value is kr1,305.2 Mil.
Saniona AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr180.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saniona AB (CHIX:SANIOS) has a EV-to-FCF of 7.24 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Saniona AB and its competitors. According to the industry distribution chart, Saniona AB ranks #122 out of 332 companies in the Biotechnology industry, placing it in the top 36.7%.
Is Saniona AB's EV-to-FCF too high?
Saniona AB's current EV-to-FCF is 7.24. The Biotechnology industry median EV-to-FCF is 16.26. Saniona AB's value of 7.24 is 55.5% below this industry median. Based on the distribution chart, Saniona AB ranks #122 out of 332 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Saniona AB has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #122 out of 332 companies for EV-to-FCF. This puts Saniona AB in the upper half of its industry. The industry median EV-to-FCF is 16.26. Saniona AB's value of 7.24 is 55.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saniona AB's current EV-to-FCF of 7.24 is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Saniona AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saniona AB's current EV-to-FCF is 7.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (CHIX:SANIOS) is currently considered Significantly Undervalued. The stock's GF Value™ is kr26.79, compared to a current price of kr12.75 — trading 52.4% below its estimated fair value. The current EV-to-FCF is 7.24 and 55.5% below the Biotechnology industry median of 16.26. Saniona AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Saniona AB (CHIX:SANIOS), the current EV-to-FCF is 7.24 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (CHIX:SANIOS) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of kr12.75 is trading 52.4% below its estimated GF Value™ of kr26.79.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for CHIX:SANIOS:
EV-to-FCF: 7.24
GF Value™: kr26.79 vs. price of kr12.75 (52.4% below fair value)
Industry Position: 55.5% below the Biotechnology median (#122 of 332)
No single metric tells the full story. See the CHIX:SANIOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
66GF Score
Get the complete analysis for CHIX:SANIOS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SANIOS has been successfully added to your 
